KMOE-2

Cat.No.: CSC-C0213

Species: Homo sapiens (Human)

Source: Blood; Peripheral Blood

Morphology: single, large, round to oval cells in suspension

  • Specification
  • Background
  • Scientific Data
  • Q & A
  • Customer Review
Cat.No.
CSC-C0213
Description
established from the peripheral blood of a 2-year-old girl with acute erythremia (Di Gugliemos disease, erythroblastosis) at diagnosis in 1978; cells were described to produce hemoglobin
Species
Homo sapiens (Human)
Source
Blood; Peripheral Blood
Recommended Medium
Morphology
single, large, round to oval cells in suspension
Disease
Acute Erythroid Leukemia
Storage and Shipping
Frozen with 70% medium, 20% FBS, 10% DMSO at about 3.5 x 10^6 cells/ampoule; ship in dry ice; store in liquid nitrogen
Synonyms
KMOE2; Kmoe2
Citation Guidance
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

KMOE-2 is a continuous human erythroid leukaemia cell line established in 1978 from peripheral blood of a 2-year-old female patient with acute erythremia (Di Guglielmo's illness). It has a hypotetraploid karyotype (modal number 82, range 80-88) and develops in suspension as solitary, big, round to oval cells.

KMOE-2 cells are cultured in conventional conditions (37°C, 5% CO2) in a nutrient-rich basal medium supplemented with serum. Their doubling time is about 40-50 h. They are seeded at a density of 0.2-0.4 × 10 6 cells/mL and achieve a peak density of about 0.6 × 10 6 cells/mL.

One of the characteristics of KMOE-2 is its erythroid differentiation potential. When treated with metabolic inhibitors such as cytosine arabinoside, the cells could synthesize hemoglobin and show benzidine-positive phenotypes. Therefore, this cell line is a useful model for researching erythropoiesis, processes of leukemic cell differentiation and screening of new therapeutic drugs against hematologic malignancies.

NFE2 Is Regulated via JAK2-Mediated Histone Tyrosine Phosphorylation

NFE2 is frequently overexpressed in myeloproliferative neoplasms (MPNs) and drives disease progression in murine models, yet its upstream regulators and downstream effectors remain unclear. Peeken et al. investigated how epigenetic modifications, specifically histone methylation and phosphorylation, regulate NFE2 expression.

They examined the role of JAK2-mediated phosphorylation. JAK2 phosphorylates Histone H3 at Tyrosine 41 (H3Y41), disrupting Heterochromatin Protein 1α (HP1α) binding. The NFE2-1A promoter harbored phospho-H3Y41, and this mark was significantly reduced by decitabine treatment.

To assess the role of JAK2 mutational status, they compared JAK2V617F mutant cell lines (HEL, UKE-1, SET-2) with JAK2 wild-type (wt) lines (K562, KMOE-2). Decitabine effectively silenced NFE2 and reduced H3K9me2 at its promoters in JAK2V617F mutant cells (Fig. 1A-C). In contrast, decitabine had no significant effect on NFE2 levels or H3K9me2 marks in JAK2wt cells (Fig. 1A, B, D). These findings indicate that decitabine selectively targets NFE2 expression in cells harboring the JAK2V617F mutation.

Decitabine-dependent downregulation of NFE2 occurs selectively in the presence of JAK2V617F.

Fig. 1. Decitabine-dependent downregulation of NFE2 occurs selectively in the presence of JAK2V617F (Peeken J C, Jutzi J S, et al., 2018).

Ask a Question

Write your own review

For research use only. Not for any other purpose.

Hot Products